Malignant fibrous histiocytoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:28 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Malignant fibrous histiocytoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Pembrolizumab and Olaparib for Patients with Resectable Soft Tissue Sarcoma https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-olaparib-for-patients-with-resectable-soft-tissue-sarcoma/ Wed, 29 Apr 2026 15:00:03 +0000 https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-olaparib-for-patients-with-resectable-soft-tissue-sarcoma/ This clinical trial is focused on studying a type of cancer known as Soft Tissue Sarcoma, specifically two subtypes: Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma. The study will explore the effects of a treatment using a medication called Pembrolizumab, which is administered through an infusion, and may also include another medication called Olaparib, taken as a tablet. The purpose of the study is to evaluate how these treatments work in patients with these specific types of cancer.

Participants in the study will receive Pembrolizumab with or without Olaparib before undergoing standard surgery to remove the cancer. This period before surgery is referred to as the “Window of Opportunity.” After the surgery, patients will continue to receive Pembrolizumab as an additional treatment. The study aims to understand the potential of these medications to enhance the body’s immune response against the cancer.

The trial will involve regular monitoring and assessments to track the effects of the treatment. This includes checking the cancer’s response to the medication and any changes in the tumor. The study will also look at the overall health and recovery of the participants over time. The goal is to gather information that could help improve treatment options for patients with Soft Tissue Sarcoma in the future.

]]> Study on Retifanlimab, Doxorubicin, and Ifosfamide for Adults with Certain Types of Sarcoma in the Abdomen, Limbs, and Trunk https://clinicaltrials.eu/trial/study-on-retifanlimab-doxorubicin-and-ifosfamide-for-adults-with-certain-types-of-sarcoma-in-the-abdomen-limbs-and-trunk/ Wed, 29 Apr 2026 14:59:58 +0000 https://clinicaltrials.eu/trial/study-on-retifanlimab-doxorubicin-and-ifosfamide-for-adults-with-certain-types-of-sarcoma-in-the-abdomen-limbs-and-trunk/ This clinical trial is focused on studying a type of cancer called retroperitoneal sarcoma, which can occur in the area behind the abdominal organs, as well as in the limbs and trunk wall. The study is investigating a treatment that combines a new medication called Retifanlimab (INCMGA00012) with standard chemotherapy drugs, Doxorubicin and Ifosfamide. These medications are given as a solution through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to explore how effective this combination treatment is in reducing the size of the tumor before surgery. Participants in the study will receive the treatment over a period of time, and the response of the tumor will be assessed by examining the tissue removed during surgery. The study will also monitor the safety of the treatment and how long patients remain free from cancer progression or survive after starting the treatment.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their well-being and to track the effects of the treatment. The study aims to provide valuable information on whether adding Retifanlimab to the chemotherapy regimen can improve outcomes for patients with this type of sarcoma. The results will help determine if this combination could become a standard treatment option in the future.

]]> Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-int230-6-vinblastine-sulfate-cisplatin-for-adults-with-metastatic-soft-tissue-sarcomas/ Wed, 29 Apr 2026 14:59:28 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-int230-6-vinblastine-sulfate-cisplatin-for-adults-with-metastatic-soft-tissue-sarcomas/ This clinical trial is focused on studying the effectiveness and safety of a new treatment called INT230-6 for patients with certain types of soft tissue sarcomas. Soft tissue sarcomas are a group of cancers that begin in the tissues that connect, support, or surround other structures and organs of the body. The specific types of sarcomas being studied include liposarcoma, undifferentiated pleomorphic sarcoma, and leiomyosarcoma. The treatment INT230-6 is a combination of two substances, vinblastine sulfate and cisplatin, which are administered directly into the tumor.

The purpose of the study is to compare the new treatment, INT230-6, with the standard care currently used in the United States for these types of sarcomas. Participants in the study will receive either the new treatment or the standard care, which may include other medications such as Halaven, Trabectedin, or Pazopanib. The study will last for a period of up to 24 months, during which the participants’ health and response to the treatment will be closely monitored.

This trial aims to provide valuable information on whether INT230-6 can improve the overall survival of patients with these challenging types of cancer. The study will also look at the side effects and overall quality of life of the participants during the treatment period. By participating in this study, researchers hope to find more effective ways to treat soft tissue sarcomas and improve outcomes for patients in the future.

]]> Study on Propranolol and Pembrolizumab for Patients with Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma https://clinicaltrials.eu/trial/study-on-propranolol-and-pembrolizumab-for-patients-with-advanced-angiosarcoma-and-undifferentiated-pleomorphic-sarcoma/ Wed, 29 Apr 2026 14:29:06 +0000 https://clinicaltrials.eu/trial/study-on-propranolol-and-pembrolizumab-for-patients-with-advanced-angiosarcoma-and-undifferentiated-pleomorphic-sarcoma/ This clinical trial is focused on studying two types of cancer: Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma. These are rare and aggressive forms of cancer that can occur in various parts of the body. The study will explore the effects of a combination treatment using two medications: Propranolol Hydrochloride and Pembrolizumab. Propranolol Hydrochloride is a type of medication known as a beta-blocker, which is commonly used to treat heart conditions but is being investigated here for its potential effects on cancer. Pembrolizumab, also known by its brand name Keytruda, is an immunotherapy drug that helps the immune system fight cancer cells.

The purpose of this study is to evaluate how well this combination treatment works in controlling the growth of these cancers over a period of three months. Participants in the study will receive both medications, with Propranolol Hydrochloride taken orally in the form of tablets and Pembrolizumab administered through an intravenous infusion, which means it is given directly into a vein. The study will monitor the participants’ health and the progression of their cancer during this time.

Throughout the study, participants will have regular visits to the clinic for treatment and monitoring. This will include various tests and assessments to track the cancer’s response to the treatment. The study aims to provide valuable information on whether this combination of medications can help improve outcomes for patients with these challenging types of cancer.

]]> Study of Pembrolizumab and Cabozantinib for Patients with Advanced Sarcomas: Undifferentiated Pleomorphic Sarcoma, Osteosarcoma, and Ewing Sarcoma https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-cabozantinib-for-patients-with-advanced-sarcomas-undifferentiated-pleomorphic-sarcoma-osteosarcoma-and-ewing-sarcoma/ Wed, 29 Apr 2026 14:23:03 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-cabozantinib-for-patients-with-advanced-sarcomas-undifferentiated-pleomorphic-sarcoma-osteosarcoma-and-ewing-sarcoma/ This clinical trial is focused on studying the effects of a combination of two medications, pembrolizumab and cabozantinib, in patients with advanced forms of a type of cancer called sarcoma. Sarcomas are cancers that can occur in various tissues like bone or muscle. The specific types of sarcoma being studied in this trial are undifferentiated pleomorphic sarcoma, osteosarcoma, and Ewing sarcoma. Pembrolizumab is a medication that helps the immune system fight cancer cells, while cabozantinib is a drug that blocks certain proteins that help cancer cells grow.

The purpose of this study is to see how well these medications work together in stopping the progression of these sarcomas over a period of six months. Participants in the study will receive pembrolizumab as an infusion, which means it is given directly into the bloodstream through a vein, and cabozantinib as a tablet taken by mouth. The study will last for up to 24 months, during which time the participants will be monitored regularly to assess the effects of the treatment on their cancer.

Throughout the study, doctors will use imaging techniques like MRI or CT scans to check the size of the tumors and see if they are responding to the treatment. The study aims to determine if the combination of pembrolizumab and cabozantinib can help control the disease and improve the quality of life for patients with these advanced sarcomas. Participants will also be monitored for any side effects from the medications to ensure their safety during the trial.

]]>